Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a small molecule experimental drug with the molecular formula C15H21NO6 and an average molecular weight of approximately 311.33 g/mol. It belongs to the class of organic compounds known as c-glycosyl compounds characterized by a sugar group bonded via carbon linkage. There is no available information on its mechanism of action or therapeutic indications; it has not been approved for clinical use and has no recorded clinical trials or patents as per current data sources. The compound appears to be primarily used in research contexts rather than as an established pharmaceutical agent.[2][3][6][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol.